
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.195 | 3.35339638865 | 5.815 | 6.58 | 5.62 | 861002 | 6.16703734 | CS |
4 | -1.4 | -18.8933873144 | 7.41 | 7.79 | 5.62 | 792562 | 6.71771313 | CS |
12 | -2.44 | -28.875739645 | 8.45 | 8.84 | 5.62 | 1169679 | 7.43249045 | CS |
26 | -5.66 | -48.500428449 | 11.67 | 13.48 | 5.62 | 962253 | 8.64436502 | CS |
52 | -16.9 | -73.7669140113 | 22.91 | 23.565 | 5.62 | 732865 | 10.9209224 | CS |
156 | -23.56 | -79.6753466351 | 29.57 | 35.73 | 5.62 | 537767 | 16.60638188 | CS |
260 | -29.62 | -83.1321919731 | 35.63 | 50.26 | 5.62 | 485362 | 23.03380089 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales